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We report the unexpected finding that loss of Hh
signaling through conditional deletion of Smooth-
ened (Smo) in the adult hematopoietic compartment
has no apparent effect on adult hematopoiesis,
including peripheral blood count, number or cell-
cycle status of stem or progenitor cells, hematopoi-
etic colony-formingpotential, long-term repopulating
activity in competitive repopulation assays, or stress
response to serial 5-fluorouracil treatment. Further-
more, pharmacologic inhibition of Hh signaling with
a potent and selective small molecule antagonist
has no substantive effect on hematopoiesis in the
mouse. In addition, Hh signaling is not required
for the development of MLL-AF9-mediated acute
myeloid leukemia (AML). Taken together, these data
demonstrate that Hh signaling is dispensable for
normal hematopoietic development and hematopoi-
etic stem cell function, indicating that targeting of
Hh signaling in solid tumors is not likely to result in
hematopoietic toxicity. Furthermore, the Hh pathway
may not be a compelling target in certain hematopoi-
etic malignancies.
INTRODUCTION
Multiple studies have explored the role of the Hh pathway in
development, but relatively few studies have addressed the
role of Hh in the hematopoietic system. Hh has been reported
to play a role in hemangioblast formation (Dyer et al., 2001);
B cell, T cell, and thymocyte development (El Andaloussi et al.,
2006; Outram et al., 2000; Sacedon et al., 2005; Uhmann et al.,
2007); erythrocyte proliferation and differentiation (Detmer
et al., 2000); and the HSC and progenitor cell compartment
(Bhardwaj et al., 2001; Gering and Patient, 2005; Trowbridgeet al., 2006). Thus, the available literature indicates that there is
an important contribution of Hh signal transduction in normal
hematopoietic development. Of further interest, mutations in
the Hh signaling pathway lead to severe developmental abnor-
malities and have been associated with several types of cancers.
For example, germline mutations in PTCH1 result in Gorlin
syndrome, which predisposes patients to medulloblastoma and
basal cell carcinoma (Corcoran and Scott, 2001; Goodrich
et al., 1997; Hahn et al., 1996; Johnson et al., 1996). More recent
studies have shown that Hh signaling is important for survival of
other tumors, including pancreatic adenocarcinoma and small
cell lung carcinoma. Based in part on these observations, Hh
antagonists are under development as potential therapeutic
agents for such cancers (Pasca di Magliano and Hebrok, 2003;
Rubin and de Sauvage, 2006).
To define the role of Hh signaling in normal hematopoietic
development and leukemogenesis, we assessed the conse-
quences of conditional deletion of the Smoothened (Smo) allele
in an in vivo knockout mouse model. Smoothened is the central
mediator of Hh signaling and is required for Hh pathway activa-
tion. Homozygous loss of function of Smo during development
results in embryonic lethality at E9.5 (Zhang et al., 2001). To
circumvent embryonic lethality, homozygous SmoC/C mice in
which exon 1 is flanked by loxP sites (Long et al., 2001) were
generated on an Mx1-Cre background, enabling inducible exci-
sion in the hematopoietic stem cell compartment using pIpC
induction of interferon expression (Kuhn et al., 1995).
RESULTS
Treatmentwith pIpCResults in Complete and Persistent
Excision of Smo
SmoC/C-Mx1Cre (hereinafter referred to as ‘‘SmoNull’’ mice) or
SmoC/C mice (hereinafter referred to as ‘‘SmoWT’’) were treated
with pIpC as described in the Experimental Procedures, and
complete excision was confirmed using a semiquantitative
three-primer PCR analysis. We observed that hematopoiesis
was supported in the absence of Smo for up to 18 months afterCell Stem Cell 4, 559–567, June 5, 2009 ª2009 Elsevier Inc. 559
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Difference in Number of LSK or Progenitor
Cells, or Their Cell-Cycle Activity
(A)SmoNullorSmoWTmice (n = 2–3 per group) were
treated with InvivoGen pIpC 200 mg and sacrificed
4 weeks after injection for complete endpoint ana-
lysis. Multiparameter flow cytometry analysis was
used to identify myeloid progenitor (Prog) and
LSK populations (top row) and the myeloid subsets
CMP, GMP, and MEP (bottom row). There was no
statistically significant difference between SmoNull
or SmoWT groups in percentage of LSK cells (p =
0.5622) or myeloid progenitors (p = 0.2948) among
live cells. Similarly, there were no differences in the
percentage of CMP (p = 0.39), GMP (p = 0.5183), or
MEP (p = 0.4823).
(B) Bar graph representation of data. Results were
analyzed in an unpaired t test. Errors bars repre-
sent SEM.
(C) Fraction of LSK (left panel) or myeloid progen-
itors (right panel) in G0/G1 versus S/G2/M in over-
lapped cell-cycle histograms for SmoNull (blue)
compared to SmoWT (red) mice.
(D) Cell-cycle analysis with Pyronin Y and Hoescht
staining for LSK (left) and myeloid progenitors
(right) shown as a percentage of live cells from
the same animals as described in (A). An unpaired
t test was used for analysis. Error bars represent
SEM.pIpC treatment (see Figures S1A and S1B available online),
indicating that there was no apparent deleterious effect of Smo
deletion on long-term hematopoiesis or survival. Furthermore,
the observation that the bone marrow remained fully excised
at 6 and 18 months, respectively, indicates that there was no
selective advantage for rare cells in which excision had not
occurred.
Loss of Smo Has No Effect on Terminally Differentiated
Hematopoietic Cells
In consonance with the above observations, there was no signifi-
cant difference in peripheral blood cell counts obtained over
time, or spleen, thymus, and liver weights between SmoNull
and SmoWT animals at 6 months after pIpC induction (Figures
S2A and S2B). Analysis of peripheral blood smears and histolog-
ical tissue sections of bone marrow, spleen, and liver, as well as
other major organ systems, also showed no apparent differ-
ences between the two groups (data not shown). Similar results
were observed in cohorts of animals each containing at least five
mice that were analyzed at 4 weeks, 12 weeks, and 6 and
18 months, respectively, after pIpC injection (data not shown).
In addition, flow cytometry analysis showed similar numbers of
T and B cells, erythroid and myeloid cells, and megakaryocytes
between SmoNull and SmoWT animals based on lineage-specific
cell-surface immunophenotyping (Figure S3).
Loss of Smo Does Not Alter the Number of
LinSac1+cKit+ Cells and Multipotent Progenitor Cells
Multiparameter flow cytometry showed no significant differences
in the number of LinSca1+cKit+ (LSK) cells as a fraction of live or
lineage-negative cells in SmoNull versus SmoWT mice (Figures 1A
and 1B). Similarly, no differences were found in the absolute560 Cell Stem Cell 4, 559–567, June 5, 2009 ª2009 Elsevier Inc.number or percent of live cells of myeloid progenitors (Figures
1A and 1B) or their subpopulations (common myeloid progenitors
[CMPs], granulocyte-monocyte progenitors [GMPs], and mega-
karyocyte-erythroid progenitors [MEPs] (Figures 1A and 1B).
There were also no apparent differences between Smo-deficient
and wild-type cells in hematopoietic colony plating potential in
methylcellulose (Figure S2C). In addition, flow cytometry-based
cell-cycle analysis of LSK or myeloid progenitor cells showed
no differences in the proportion of cells in G0/G1 and S/G2/M
between SmoNull and SmoWT in absolute numbers or percent of
live cells (Figures 1C and 1D).
Loss of SmoDoes Not Affect BoneMarrowRepopulation
after Transplantation
We next assessed whether loss of Smo had any impact on repo-
pulating the bone marrow after bone marrow transplantation.
We transplanted 1 3 106 bone marrow cells from SmoNull and
SmoWT animals into lethally irradiated recipients. After engraft-
ment had occurred 3 weeks after transplantation, recipient
mice were treated with pIpC 25 mg/g mouse weight to induce
excision of Smo. Again, we confirmed that complete excision
was achieved in the peripheral blood 4 weeks after the first
dose of pIpC was given (data not shown). Complete blood counts
were obtained 4 and 12 weeks after the pIpC was given and did
not show any differences between mice that received bone
marrow from SmoNull and SmoWT donors. Mice were sacrificed
12 weeks after pIpC injection for complete analysis. Again, no
significant differences were observed in peripheral blood cell
counts, spleen, thymus and liver weights, histopathology of all
major organ systems, colony-forming unit (CFU) potential, and
flow cytometric analysis of terminally differentiated hematopoi-
etic cells (data not shown). We repeated the same experiment
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T Cell and Thymocyte Development
Bone marrow of SmoNull or SmoWT mice was har-
vested and transplanted into lethally irradiated
B6.SJL recipients (n = 6 per group), which were
treated with 25 mg/gram pIpC 3 weeks after
engraftment. Thymi were harvested 12 weeks
after pIpC treatment to analyze the T cell subpopu-
lations and thymocyte development.
(A) Flow cytometry analysis was performed to iden-
tify CD4+ T helper cells, CD8 + cytotoxic T cells,
and CD4+/CD8+ double-positive (DP) T cells, as
well as thymocyte development (DN1-DN4) char-
acterized by CD44 and CD25 characteristics.
There was no difference between SmoNull or
SmoWT mice in regards to T cell subpopulations
(p = 0.9983) or thymocyte developmental stages
(p = 1.0).
(B) Representative populations shown in flow
scattergrams.
(C) Percentage of TCRab-rearranged cells gated
on CD4+, CD8+, or CD4+/CD8+ T cells. There
was no statistically significant difference between
thymocytes obtained from SmoNull or SmoWT mice
(p = 0.9917).
(D) Representative data for CD4+ and CD4+/CD8+
populations are shown in a histogram. An unpaired
t test was used for statistical analysis. Error bars
represent SEM.by treating SmoNull and SmoWT animals with pIpC first and then
transplanting the harvested bone marrow into lethally irradiated
recipient mice. We performed the same comprehensive analysis
as outlined above and again observed comparable results, indi-
cating that Smo is not required for repopulating the bone marrow
after transplantation.
Hh Signaling Is Dispensable for Thymocyte
Development
Given previous reports in the literature that loss of Smo plays
a role in thymocyte development, we analyzed thymocyte devel-
opment in mice after bone marrow transplantation. The differen-
tiation pattern of CD4-CD8 double-negative (DN) thymocytes
was assessed by flow cytometry and defined by immunopheno-
typic characteristics of CD25 and CD44 expression patterns
leading to various stages of T cell maturation from DN1 (CD25,
CD44+), to DN2 (CD25+, CD44+), to DN3 (CD25+ CD44), to
DN4 (CD25, CD44) thymocytes. In addition, we analyzed the
contributions of TCRab and TCRgd of CD4-positive helper cells,
CD8-positive cytotoxic T cells, or CD4- and CD8 double-positive
T cells.
In contrast to the previously reported literature, we did not
observe any differences in the absolute number or percent of
live cells of CD4+ helper cells, CD8+ cytotoxic T cells, or
CD4+CD8+ T cells (Figures 2A and 2B). Neither did we detect
any abnormal maturation pattern of immature DN thymocytes
by flow cytometry (Figures 2A and 2B). We also did not identify
any aberrant T cell population by CD4/CD8 and TCRab charac-
teristics (Figures 2C and 2D). The TCRab-positive T cells were
negative for TCRgd (data not shown). Comparable results were
noted in a similar experiment in which pIpC was given prior to
bone marrow transplantation.Loss of Smo Does Not Affect Stem Cell Function
in a Competitive Repopulation Assay
These data indicate that loss of Smo, the central cellular effector
of Hh signaling, does not have any apparent effect on hemato-
poiesis in adult mice in an in vivo conditional knockout mouse
model system. However, to formally test functional HSC activity
in the context of Smo deficiency, we performed competitive
repopulation assays. Whole bone marrow was harvested from
SmoWT/CD45.2 or conditional deleted SmoNull/CD45.2 mice, mixed
at varying ratios with competitor B6.SJLF1CD45.1/CD45.2 cells,
and transplanted into lethally irradiated B6.SJLCD45.1 recipients.
Baseline flow cytometric analysis of chimerism confirmed the
expected ratios of SmoNull donor and SmoWT competitor cells
3 weeks after transplantation (data not shown). Mice were
treated with pIpC 3 weeks after engraftment to eliminate any
potential cytokine effect that pIpC might have on homing and
engraftment. Complete excision of Smo was confirmed using
semiquantitative three-primer PCR 4 weeks after treatment
with pIpC (Figure S1C).
Flow cytometric analysis of the adult hematopoietic compart-
mentat8 weeks (datanotshown), andat studyendpoint16 weeks
after treatment with pIpC, showed no statistically significant
difference between SmoNull and SmoWT donors (Figure 3). The
observation that there is no disadvantage for Smo-deficient
bone marrow cells in competitive repopulation assays in
secondary recipient mice is in consonance with our previous
experiment (Figure S1B) in primary animals showing no compet-
itive disadvantage for Smo-excised cells 18 months after exci-
sion. In addition, there were no significant differences between
the relative contribution of SmoNull versus SmoWT donors to
lymphocyte, T cell, myeloid, erythroid cells, or megakaryocyte
lineages (data not shown) and no differences in spleen or liverCell Stem Cell 4, 559–567, June 5, 2009 ª2009 Elsevier Inc. 561
Cell Stem Cell
Hh Is Dispensable in Adult Murine HematopoiesisFigure 3. Loss of Smo Does Not Affect
Competitive Repopulating Activity
Flow cytometric analysis of whole bone marrow
cells using CD45.1 and CD45.2 surface marker
labeling to identify CD45.1-positive recipient (left
upper quadrant), CD45.1/CD45.2 double-positive
competitor (right upper quadrant), or CD45.2
donor (right lower quadrant) cell populations.
SmoWT/CD45.2orSmoNull/CD45.2donor bone marrow
was transplanted together with a competitor WT
bone marrow from B6.SJL F1CD45.1/CD45.2 mice
into B6.SJLCD45.1 recipients (n = 15 per group).
The following donor:competitor ratios were used:
1:0, 3:1, 1:1, 1:3, and 0:1 (n = 3 per subgroup).
Recipient mice were treated with pIpC 3 weeks
after engraftment. Donor-to-competitor chimerism
analysis of the bone marrow at 16 weeks is shown
for SmoNull/CD45.2 (top) or SmoWT/CD45.2 mice at
representative donor:competitor ratios of 1:0
(left), 1:1 (middle), and 0:1 (right). Analysis of the
peripheral blood and spleen showed similar
results.weight or histopathology of paraffin-embedded tissue sections of
heart, lung, gastrointestinal tract, kidney, spleen, liver, or bone
marrow (data not shown).
Hh Signaling Is Dispensable under Conditions
of Hematopoietic Stress
Overall, these data indicate that Hh signaling is dispensable for
the reconstitution of long-term hematopoiesis in competitive
repopulation assays using an experimental design in which
Smo is excised after transplantation. To determine whether Hh
signaling might be important for stress response in the hemato-
poietic system, we tested response to serial treatment with
5-fluorouracil (5-FU) (Cheng et al., 2000) (Figure 4). We observed
no differences in complete blood counts or survival between
SmoNull and SmoWT in response to 5-FU treatment.
HhAntag and rShh Agonist Do Not Affect Hematopoietic
Colony-Forming Potential In Vitro
These genetic studies collectively indicate that Hh signaling plays
a nominal role in normal adult hematopoietic development, main-
tenance, or stress response. These findings would suggest that
systemic pharmacologic inhibition of the Hedgehog pathway,
as a therapeutic approach for a spectrum of solid tumors, would
be expected to have minimal hematopoietic toxicity. To formally
test this hypothesis, we assessed the effect of pharmacologic
inhibition of Hh on the hematopoietic system in vitro and
in vivo. There are several low-affinity pharmacologic inhibitors
of Hh signaling, such as cyclopamine, but it is difficult to ascertain
the consequences of off-target effects at the high micromolar
concentrations required for Hh inhibition (Taipale and Beachy,
2001). For this reason, we tested a high-affinity highly selective
Hh antagonist (HhAntag) (Yauch et al., 2008), as well as a
recombinant Sonic Hedgehog agonist (rShh), in hematopoietic
colony-forming assays. We treated normal murine whole bone
marrow cells with inhibitor HhAntag at a concentration 7500-
fold higher than the IC50 for cellular inhibition of Hh signaling
alone, and rShh ligand at 100 ng/ml. We observed no effect
on hematopoietic colony-forming (CFU-GM, BFU-E, and CFU-562 Cell Stem Cell 4, 559–567, June 5, 2009 ª2009 Elsevier Inc.GEMM) potential for these agents, either alone or in combination
(Figure 5A).
HhAntag or rShh Agonist Does Not Affect Blood Cell
Counts In Vivo
To confirm these findings in vivo, we treated mice for 3 weeks
twice daily by oral gavage with 100 mg/kg HhAntag or its vehicle,
a dosing regimen that results in continuous in vivo suppression of
the Hh pathway (Yauch et al., 2008). We confirmed a level of
Figure 4. Response to Stress with Serial 5-FU Experiment Does Not
Lead to Any Changes in Peripheral Blood Counts or Overall Survival
in SmoNull Mice
Peripheral blood counts of SmoNull or SmoWT mice that received sequential
5-FU treatment 3 weeks after pIpC treatment. No differences in (A) WBC
(n = 5, p = 0.7130), (B) Hematocrit (Hct) (n = 5, p = 0.9524), or (C) platelet count
(n = 5, p = 0.6867) was observed over time. An unpaired t test was used for
statistical analysis. Error bars represent SEM. (D) Survival outcome after
sequential 5-FU treatment. 5-FU was administered i.p. weekly at a dose of
150 mg/kg in a survival study. Results were analyzed using a log rank test
and expressed as Kaplan-Meier survival curves (n = 5, p = 0.7569).
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MLL-AF9-Mediated Serial Replating Activity
and Leukemogenesis; and Pharmacological
Inhibition of Hh Signaling with HhAntag Has
No Effect on Colony-Forming Potential
(A) Modulation of the Hedgehog signaling does
not impact colony formation. Normal murine bone
marrow cells (1.33 105) per condition were plated
in methylcellulose supplemented with SCF, IL-3,
IL-6, and erythropoietin in the presence or absence
of rSHH and/or the hedgehog antagonist HhAntag.
There was no significant difference in CFU-GM,
BFU-E, or CFU-GEMM when comparing vehicle
versus HhAntag versus rShh agonist versus
HhAntag + rShh (n = 3 per group, p = 0.5741,
0.6338, and 0.6935, respectively; one-way ANOVA
test). Error bars represent SEM.
(B) SmoNull or SmoWT bone marrow cells were ret-
rovirally transduced with MSCV-MLL-AF9/GFP
and then serially replated on methylcellulose
media for five rounds. Over the course of five
rounds of replating, there was no significant differ-
ence in the absolute number of colonies observed
(n = 7, p = 0.2424 using an unpaired t test). Error
bars represent SD.
(C) SmoNull or SmoWT bone marrow cells retrovir-
ally transduced with MLL-AF9/GFP were trans-
planted into lethally irradiated B6.SJL WT recipient mice. No significant difference in the disease latency or overall survival of SmoNull compared to SmoWT
mice was noted (n = 5, p = 0.1448, log rank test). Results are shown in a Kaplan-Meier survival curve.
(D) Flow cytometric analysis demonstrating no difference in immunophenotype of Mac-1 and c-kit double-positive AML cells in SmoNull compared to
SmoWT samples.HhAntag of 4.1 ± 1.3 mM at 6 hr after oral dosing and a concom-
itant 2.3 ± 0.2-fold pharmacodynamic reduction in Gli1 expres-
sion in lung as a surrogate tissue. No significant differences in
white blood cells, neutrophils, lymphocytes, or monocytes
were noted in treated mice despite continued blockade of the
Hh pathway (Table 1), although a slight reduction in hemoglobin
was observed that reached statistical significance.
Hh Signaling Is Dispensable for MLL-AF9-Mediated
Leukemogenesis
These data convincingly demonstrate that the Hh pathway does
not appear to play a central role in normal adult hematopoietic
development, or at a minimum that there are highly redundant
functional pathways that can compensate for either genetic or
pharmacologic inhibition of Hh signaling in the hematopoietic
system. However, these findings do not discount the possibility
that Hh is important in leukemogenesis. Indeed, the limited liter-
ature available suggests that Hh may play an important role in
hematologic malignancies. For example, Hh ligand promotesexpansion, but not differentiation, of tumor stem cells in multiple
myeloma (MM), whereas blockade of the Hh pathway inhibits
clonal expansion of purified MM stem cells (Peacock et al.,
2007). Hh derived from BM stroma acts as a survival factor for
murine B cell lymphoma cells, and blockade of Hh signaling
inhibits lymphoma growth in vivo (Dierks et al., 2007). Recent
reports also indicate that mantle cell lymphoma cells show
impaired proliferation after exposure to cyclopamine (Hegde
et al., 2008) and that deregulation in Shh signaling appears to
be associated with chronic myeloid leukemia (CML) progression
(Sengupta et al., 2007). In addition, it has been reported that Hh
signaling may play an important role in maintenance of leukemia
stem cells in a murine model of CML-like disease (Dierks et al.,
2008).
To characterize the role of the Hh pathway in leukemogenesis,
we utilized in vitro serial replating assays and in vivo assays of
leukemogenesis. Whole bone marrow derived from SmoNull or
SmoWT animals was transduced with retrovirus harboring the
leukemia-associated disease allele MLL-AF9, which confersTable 1. Hematologic Analysis of HhAntag-Treated Mice Following 21 Days of Continuous Treatment
Treatment Absolute Cell Count (1 3 103 Cells) g/dL %
WBC NEUT LYMPH MONO RBC HGB HCT
MCT Mean 9.66 0.77 8.31 0.19 10.08 15.00 44.70
Stdev 0.84 0.13 0.96 0.23 0.39 0.53 2.00
HhAntag Mean 8.51 0.70 7.53 0.11 9.30 13.92 41.82
Stdev 0.71 0.24 0.74 0.08 0.42a 0.55a 1.58
WBC, white blood cell; NEUT, neutrophil; LYMPH, lymphocyte; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit.
a p < 0.05; unpaired t test.Cell Stem Cell 4, 559–567, June 5, 2009 ª2009 Elsevier Inc. 563
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stroma as an in vitro surrogate for leukemia stem cell activity
(Krivtsov et al., 2006; Somervaille and Cleary, 2006). We
observed no differences in replating potential for MLL-AF9-trans-
duced cells when comparing bone marrow cells derived from
Smo-deficient versus Smo wild-type animals (Figure 5B). We
also performed in vivo analysis of leukemogenesis for the MLL-
AF9 allele to assess the effects of loss of function of Smo. Bone
marrow cells derived from SmoNull or SmoWT animals were trans-
duced with MLL-AF9 retrovirus and transplanted into lethally irra-
diated wild-type recipient mice, leading to development of an
acute myeloid leukemia (AML). Based on the Bethesda classifi-
cation for nonlymphoid hematopoietic neoplasms in mice, the
disease is best classified as monocytic leukemia (Kogan et al.,
2002). Expression of dim Gr-1, and variable-to-bright Mac-1
(CD11b), is supportive of this diagnosis (data not shown). We
observed no statistically significant differences in disease pene-
trance, latency, or phenotype between the two groups, with
development of fully penetrant acute monocytic leukemia in
recipients of MLL-AF9-transduced SmoNull versus SmoWT bone
marrow (Figures 5C and 5D). To confirm that the MLL-AF9 leuke-
mias could not be attributed to a high degree of selective advan-
tage from transduction of rare unexcised cells, we demonstrated
complete excision of Smo in MLL-AF9 leukemia cells (data not
shown). These data indicate that Hh is dispensable for the devel-
opment of AML mediated by MLL-AF9. However, it is important
to note that other leukemogenic alleles should be tested in this
system. Furthermore, these findings do not exclude the possi-
bility that AMLs in humans might be sensitive to pharmacologic
inhibition of Hh signaling. However, they do indicate that the
pathway is not requisite for leukemogenic potential of an MLL
fusion gene.
DISCUSSION
Taken together, these genetic and pharmacologic data support
the unexpected conclusion that the Hedgehog pathway is not
required for hematopoietic homeostasis in the adult mouse.
These findings do not necessarily mitigate against findings
from other investigators indicating that Hh signaling may play
a role in proliferation of primitive human HSC through BMP regu-
lation (Bhardwaj et al., 2001) or in modulation of cell cycle in
regulation of HSC regeneration (Trowbridge et al., 2006). Our
data would, however, indicate that Hh signaling is not required
for these functions and that redundant mechanisms may be in
play. The fact that Smo and Ptch1 are expressed in LSK and
myeloid progenitors, but that their downstream transcription
factor targets Gli1, Gli2, and Gli3 are not detectable (Gao et al.,
2009 [this issue of Cell Stem Cell]), supports the hypothesis
that Hh pathway components are expressed in the hematopoi-
etic system but that the pathway is inactive in the adult murine
hematopoietic system, given the lack of Gli expression.
This disparity between requirements during development
compared with adult hematopoiesis is not without precedent.
For example, the stem cell leukemia (SCL/tal-1) gene is essential
for primitive hematopoiesis but is dispensable for HSC engraft-
ment, self-renewal, and differentiation in the adult (Mikkola
et al., 2003). On the other end of the spectrum, Etv6 (Tel) is not
required for establishment of definitive hematopoiesis during564 Cell Stem Cell 4, 559–567, June 5, 2009 ª2009 Elsevier Inc.development but is essential for maintenance of the HSC
compartment in the adult (Hock et al., 2004). Smo is another
example of genes that may play differential roles in develop-
mental versus adult hematopoiesis.
Our data showing no effect on T cell development in the adult
also vary from literature reports showing a defect in T cell devel-
opment (El Andaloussi et al., 2006). The previous report assessed
T cells derived from thymi of neonates 2 weeks after excision with
pIpC, whereas we assessed T cells in adult mice 4–6 weeks after
birth and then 4 weeks after pIpC injection. These data might
also suggest a differential requirement for Hh signaling during
development compared with adult life. Finally, these findings
vary from that observed in zebrafish where Hh signaling has
been shown, using genetic strategies, to be requisite for adult
blood stem cell formation (Gering and Patient, 2005). This differ-
ence may be a species-specific difference or may reflect a differ-
ential requirement for Hh signaling in the hematopioetic system
during development compared with adult hematopoiesis.
Very recent data suggest that Hh signaling may play an impor-
tant role in leukemia stem cell function in a BCR-ABL-induced
model of murine hematopoietic disease, based in part on use of
cyclopamine analogs (Dierks et al., 2008; Zhao et al., 2009).
Although we observe no impact in MLL-AF9-mediated leukemo-
genesis in the absence of Smo, suggesting that the pathway does
not play a critical role in initiation of leukemia, it remains plausible
that Hh signaling could be effectively targeted in leukemias that
arise de novo, or that there are allele-specific differences in
requirement for Hedgehog signaling. For example, activated
kinases like BCR-ABL that do not have the potential for activating
self-renewal programs in stem cells may be more reliant on these
pathways than alleles such as MLL fusion genes that can confer
properties of leukemia stem cells to committed progenitors
(Cozzio et al., 2003; Huntly et al., 2004; Krivtsov et al., 2006).
A recent publication from Zhao et al. indicates that Hh
signaling plays an important role in hematopoietic stem cell
renewal and in maintenance of cancer stem cells in CML (Zhao
et al., 2009). The disparity in the stem cell phenotype between
this report and the extensive in vitro and in vivo studies reported
herein and independently by Gao et al. (2009) may be explained
by methodological differences. These include the use of a non-
conditional Vav-Cre allele that would be predicted to result in
Smo loss during embryonic development, in contrast with condi-
tional excision in the adult hematopoietic compartment induced
by pIpC with the Mx1-Cre allele. In addition, the use of mixed
background for competitive repopulation assays in the Zhao
study compared with fully backcrossed C57/Bl6 in our study
could influence competitive repopulation potential based on
minor histocompatibility differences, among other possibilities.
Lastly, these findings do indicate that pharmacologic inhibition
of the Hh pathway for the treatment of life-threatening diseases
such as pancreatic cancer, colorectal cancer, and metastatic
basal cell carcinoma should not be met with unmanageable
hematopoietic toxicities.
EXPERIMENTAL PROCEDURES
CFU Assay
Bone marrow cells were plated in methylcellulose medium (MethoCult3434;
Stem Cell Technologies) at a density of 20,000 cells/ml media according to
Cell Stem Cell
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7–10 days after plating. For the serial replating assay, SmoNull or SmoWT
bone marrow was retrovirally transduced with MLL-AF9 MSCV-GFP as previ-
ously described. Whole bone marrow cells were then plated at a concentration
of 20,000 cells/mL. Colonies were counted after 7 days, removed from the plate
by dilution with RPMI containing 10% FBS and 1% penicillin/streptomycin,
washed in PBS with 2% FBS, and replated onto a new plate for up to five
rounds.
For the pharmacological experiments, hematopoietic colony assays were
carried out in complete methylcellulose medium (MethoCult GF, Stem Cell
Technologies) according to the instructions of the manufacturer in the pres-
ence of vehicle, rSHH (final concentration 100 ng/ml), and/or the Hedgehog
pathway antagonist HhAntag (final concentration 300 nM). Colonies were
scored on day 8 after plating, and the experiment was carried out in triplicate.
Cell Staining and Flow Cytometry Analysis
The contribution of definitive hematopoietic cells of bone marrow, spleen,
and peripheral blood was verified by staining with monoclonal antibodies
conjugated to fluorescein isothiocyanate (FITC), allophycocyanin (APC),
phycoerythrin (PE), or peridinin-chlorophyll-protein complex (perCP), all from
BD Biosciences. The following antibodies were used: CD45, CD3, B220,
CD4, CD8, Gr-1, Mac-1, c-kit, CD34, CD41, Ter119, CD45.1, and CD45.2.
Surface marker expression was visualized with a FACSCalibur (Becton Dickin-
son) and was analyzed with FlowJo software. Stem and progenitor cell popula-
tion analysis was done by lineage depletion of whole bone marrow cells using
unconjugated murine lineage antibodies CD3, CD4, CD8, Gr-1, B220/CD45R,
CD19, IL-7R, or Ter119, which were labeled using goat anti-rat PECy5. The
following antibodies were used for the LSK compartment (containing long-
term and short-term HSCs) and progenitor staining: CD34, FcRgII, c-kit, and
Sca-1. LSK cells were defined by Sca-1+ and c-kit+ expression. Progenitor
cells were defined by CD34+, FcRgII dim (CMP), CD34 dim, FcRgII dim
(MEP), and CD34+, FcRgII+(GMP). Flow analysis for LSK or progenitor cells
populations was done by using FACSAria (Becton Dickinson) and analyzed
as above. For cell-cycle analysis, Pyronin Y and Hoescht staining were used
as described elsewhere (Cheng et al., 2000).
Mouse Strains
Smoothened conditional knockout mice (Smotm2Amc), noted as SmoC/C (Long
et al., 2001), were obtained from Jackson Laboratories. Mice were housed in
a sterile barrier facility approved by the IUCAC at Children’s Hospital Boston.
SmoC/C mice were backcrossed to C57/Bl6 for eight generations and then
crossed with Mx1-Cre, also in a C57/Bl6 background (Kuhn et al., 1995).
Genotyping PCR
Routine PCR genotyping of the Smo alleles was performed on tail DNA by using
a Promega PCR Master Mix kit. The total PCR volume was 13ml, including 1ml of
1:10 diluted tail DNA. The following primers were used to amplify the Smo
floxed target gene: Smo-1 forward, 50-GCAAGCTCGTGCTCTGGTC-30; and
Smo-2 reverse, 50-CCGGTGGATGTGGAATGTG-30, which generated a 250 bp
band. For the Mx1-Cre genotyping, QIAGEN PCR Core kit was used. The
primers used were Cre reverse, 50-ACGACCGGCAAACGGACAGAAGCA-30;
and Mx1 forward, 50-CCCAACCTCAGTACCAAGCCAAG-30. The total PCR
volume was 25 ml, including 1 ml of undiluted tail DNA.
Induction of Mx1-Cre Expression with pIpC
Animals were treated with polyinosine-polycytidylic acid (pIpC, Sigma) by
intraperitoneal (i.p.) injection at 10 weeks of age. Doses up to 25 mg/g mouse
weight (or maximum dose 600 mg, whichever was less) were given every other
day for a total of three doses. Mice were analyzed between 1 and 18 months
after the first injection.
Detection of SmoC Excision
DNA was isolated from whole peripheral blood or from frozen single-cell
suspensions of spleen, thymus, and bone marrow using the QIAamp DNA
blood mini kit or tissue kit (QIAGEN). DNA was quantified and diluted to a stan-
dard concentration of 25 ng for PCR.Semiquantitative Three-Primer PCR for Excision Analysis
A three-primer PCR was performed with the following primers: common
reverse primer (CCATCACGTCGAACTCCTGGC) at a 13 concentration in
the PCR reaction; forward primer for amplification of nonexcised (‘‘floxed’’)
SmoC allele (CCGATTCGCAGCGCAT) at a 0.53 concentration; and forward
primer for amplification of excised SmoC allele (GGCCTGCGCTGCTCAACA
TGG) at a 0.53 concentration. Annealing temperature was 60C.
Mouse Analysis and Organ Collection
Peripheral blood was collected from the retroorbital cavity using a heparinized
glass capillary tube. Complete peripheral blood count analysis including
a differential blood count was obtained by using Hemavet (Drew Scientific).
For histological analysis, peripheral blood smears were stained with a standard
Wright-Giemsa stain. Mice were euthanized, and all relevant organs were
collected, fixed in 10% formalin, and subsequently paraffin embedded.
Histological sections (4 mm) were stained by hematoxylin and eosin (H&E) in
a histopathology core facility (Brigham and Women’s Hospital).
Bone Marrow Transplant Experiments
For the competitive bone marrow transplant experiment, SmoWT/CD45.2 or
SmoNull/CD45.2 donor bone marrow was transplanted in various ratios together
with a competitor WT bone marrow from B6.SJL F1CD45.1/CD45.2 mice into
B6.SJLCD45.1 recipients. A total of 2 3 106 cells were transplanted with donor
to competitor ratios of 1:0, 3:1, 1:1, 1:3, and 0:1, respectively. This approach
enabled differentiation between donor, competitor, and recipient bone marrow
populations using flow cytometry analysis with fluorochrome-labeled anti-
bodies for CD45.1 or CD45.2. Helper bone marrow cells were generated by
crossing C57/Bl6 and SJL mice and using offspring from the first generation
that were CD45.1/CD45.2 double positive.
For retroviral bone marrow transplant experiments, SmoNull or SmoWT B6 F8
mice were injected i.p. with pIpC 25 mg/g every other day for three doses. Three
weeks after the first pIpC injection, peripheral blood was collected. DNA was
extracted to confirm Smo excision by using the three-primer PCR technique
previously described. Mice were then treated with one dose of intraperitoneal
5-FU 150 mg/kg on day 8. Bone marrow cells were harvested on day 2
and ‘‘spin infected’’ twice with a MSCV retrovirus expressing MLL-AF9/GFP
(kindly provided by Dr. S. Armstrong) (Krivtsov et al., 2006; Scholl et al.,
2007). Retrovirally transduced SmoNull orSmoWT bone marrow was then trans-
planted into lethally irradiated B6.SJL WT recipient mice. A subset of bone
marrow cells was used for serial replating on methylcellulose as described
above. Peripheral blood was collected 4 weeks after transplantation to evaluate
peripheral blood counts. Mice were euthanized at the clinical onset of leukemia
determined by signs of distress, such as decreased activity and hepatospleno-
megaly. Peripheral blood and all relevant mouse organs were collected as
described above and used for comprehensive analysis, including CBC with
differential, organ weight, histopathology, and flow cytometric analysis.
Serial 5-FU Experiment
5-FU was administered weekly at a dose of 150 mg/kg i.p. toSmoNull orSmoWT
mice. Sequential blood counts prior to 5-FU therapy (day 1) and on days 5, 7,
11, and 14 were obtained, and survival was monitored.
Pharmacological Experiments with HhAntag
Female 6- to 8-week-old C57/BL6 mice were obtained from Charles River
Laboratories (Wilmington, MA). All mice were housed and maintained accord-
ing to the animal use guidelines of Genentech, Inc., conforming to State of
California legal and ethical practices. Mice were treated with either control
(MCT; 0.5% methyl cellulose, 0.2% tween-80 at 10 ml/kg) or 100 mg/kg
HhAntag (10 mg/ml solution in MCT) twice daily for 21 days by oral gavage
and blood collected 6 hr following the final dose by cardiac puncture for anal-
ysis. Analysis was performed on a Cell Dyn 3700 System from Abbott Labora-
tories, Inc. (Abbott Park, IL).
RT-PCR
Hh pathway genes were quantitatively assessed in frozen tissues by TaqMan
using standard techniques. Transcript levels were normalized to the ribosomal
protein L19 (RPL19) and results expressed as normalized expression values
(= 2  DCt).Cell Stem Cell 4, 559–567, June 5, 2009 ª2009 Elsevier Inc. 565
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HhAntag was detected in plasma following oral administration 6 hr following the
last daily dose. Whole blood was collected via cardiac puncture, placed in
heparinized Eppendorf tubes on ice, and centrifuged at 10,000 3 g for 4 min.
The plasma supernatant was added to internal standard solution, mixed by vor-
texing, and centrifuged. Sample extract was assayed for HhAntag by LC/MS/
MS analysis. Plasma levels were calculated using an authentic standard curve.
SUPPLEMENTAL DATA
Supplemental Data include three figures and can be found with this article online
at http://www.cell.com/cell-stem-cell/supplemental/S1934-5909(09)00152-0.
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